Establishing Best Treatment Strategy for T4 Esophageal Cancer

The goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for T4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. The main questions it aims to answer are: * Does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate? * Does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? Researchers will analyze the above data to see if the new treatment approach works to treat T4 esophageal cancer. Participants will: * Re

Trial Details

NCT ID
NCT06531434
Phase
PHASE1 / PHASE2
Sponsor
National Cheng-Kung University Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • "Docetaxel", "Cisplatin", "fluorouracil", "Radiation"
Locations (sample)
  • Tainan, Taiwan, Taiwan|22.99259,120.20507

Key Eligibility Criteria

  • Histologically confirmed esophageal squamous cell carcinoma
  • Tumor or lymph nodes invade adjacent organs (T4 stage)
  • Aged between 18-70 years old
  • Patient health status score Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →